Loading
Drug tests normally use cells from the original tumour. Growing the rarer cells found in blood would test drugs against the cells that are actually travelling.
Cultures and xenografts derived from circulating tumour cells have been established in small-cell lung, breast and prostate cancer, with success rates that rise with CTC burden. They capture the metastasis-competent population and can be sampled repeatedly without a biopsy. Scaling the protocols, publishing failure rates honestly, and linking drug sensitivity to subsequent clinical course would create the first functional assay of metastatic competence.
Shares Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients, Liquid biopsy (ctDNA).
Shares Are 90% of deaths from cancer caused by metastases?, Patient-derived xenografts, Metastasis is understood least and studied last, Patient-derived organoids.
Shares Caroline Dive, Are 90% of deaths from cancer caused by metastases?, Metastasis is understood least and studied last, Liquid biopsy (ctDNA).
Shares Patient-derived xenografts, Metastasis is understood least and studied last, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Patient-derived xenografts, Functional (ex vivo) drug testing, Lab models that fail to predict what happens in patients.
Shares Patient-derived xenografts, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Fiona Blackhall, Caroline Dive, Patient-derived xenografts, Liquid biopsy (ctDNA).
Shares Patient-derived xenografts, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.